Doctor Reveals TOP Peptides & Supplements To Help You Avoid Dementia

The Growing Case for Proactive Brain Protection

Dementia is not a single disease. It is an umbrella term covering Alzheimer's, vascular dementia, Lewy body dementia, frontotemporal dementia, and several other conditions that share one terrifying outcome: progressive loss of cognitive function. Dr. Ashley Froese approaches dementia prevention from a functional medicine perspective, outlining which peptides and supplements have the strongest evidence for protecting brain health before decline begins. The key word there is "before." By the time symptoms appear, decades of damage have already accumulated.

The statistics are sobering. Alzheimer's disease alone affects more than 6 million Americans, and that number is projected to nearly double by 2050. Current pharmaceutical treatments for established dementia offer modest symptom management at best. None reverse the disease. None halt its progression in a meaningful way. This reality has shifted attention toward prevention, and the earlier prevention starts, the more effective it is likely to be. Dr. Froese argues that brain protection should begin decades before anyone would expect cognitive problems, ideally in your 30s and 40s.

What makes this video particularly useful is that it goes beyond the standard supplement list and incorporates peptides into the prevention strategy. Most brain health content stops at omega-3s and curcumin. Dr. Froese adds several peptides with genuine mechanistic relevance to neurodegeneration, and she explains why each one matters rather than just listing them.

Peptides With Neuroprotective Evidence

Semax leads the peptide portion of the discussion. As a synthetic ACTH fragment that dramatically upregulates brain-derived neurotrophic factor (BDNF), Semax directly supports the neurotrophic signaling that declines with age and in neurodegenerative disease. BDNF is essential for maintaining existing neural connections and creating new ones, and low BDNF levels are consistently associated with increased dementia risk. The Russian clinical experience with Semax in stroke and brain injury patients provides evidence that it can support neural recovery and protection in real-world settings.

Selank gets attention for its anxiolytic and immune-modulating properties. Chronic stress and the inflammation it produces are recognized risk factors for cognitive decline. By addressing anxiety without cognitive impairment and by modulating the immune-inflammatory pathways that contribute to neurodegeneration, Selank serves a dual protective role. The ability to manage stress without the cognitive costs of benzodiazepines is particularly relevant for long-term brain health, since chronic benzodiazepine use itself has been associated with increased dementia risk in some epidemiological studies.

BPC-157 enters the conversation through its effects on blood vessel formation and inflammatory modulation. Vascular health is increasingly recognized as central to brain health. The brain depends on constant blood flow for oxygen and nutrient delivery, and vascular dysfunction is a major contributor to both vascular dementia and Alzheimer's disease. BPC-157's ability to promote angiogenesis and modulate nitric oxide pathways could support the vascular infrastructure that the brain depends on, though direct evidence for brain-specific vascular effects in humans is still limited.

Epithalon rounds out the peptide recommendations through its telomerase activation and melatonin restoration effects. Telomere shortening in brain cells contributes to cellular senescence and reduced regenerative capacity. Melatonin decline with aging correlates with sleep disruption, and poor sleep is one of the most consistently identified risk factors for Alzheimer's disease. During deep sleep, the brain's glymphatic system clears beta-amyloid and tau proteins, the toxic aggregates that define Alzheimer's pathology. Restoring healthy melatonin cycling through Epithalon could support this critical clearance process.

The Supplement Foundation

Dr. Froese also covers the supplement base that she recommends alongside peptides. Omega-3 fatty acids, particularly DHA, are structural components of brain cell membranes and are critical for maintaining membrane fluidity and receptor function. Low omega-3 status is associated with faster cognitive decline and increased dementia risk in observational studies. The dose she recommends is higher than standard supplementation, typically 2 to 4 grams of combined EPA and DHA daily.

Lion's mane mushroom extract gets a strong recommendation based on its ability to stimulate nerve growth factor (NGF) production. NGF is essential for the maintenance and repair of neurons in the central and peripheral nervous systems. Several clinical studies have shown cognitive improvements in people with mild cognitive impairment who took lion's mane extract, making it one of the better-evidenced natural nootropics.

Phosphatidylserine, a phospholipid that is a major component of neuronal cell membranes, has shown benefits for cognitive function in multiple clinical trials, particularly in elderly subjects with declining memory. Dr. Froese recommends 100 to 300 mg daily and notes that it is one of the few supplements for which the FDA has allowed a qualified health claim related to cognitive function.

Magnesium threonate (Magtein) is highlighted for its unique ability among magnesium forms to cross the blood-brain barrier and increase brain magnesium levels. Magnesium is involved in over 600 enzymatic reactions in the body, and brain magnesium levels decline with age. Clinical studies have shown that magnesium threonate supplementation can improve memory and executive function, particularly in older adults with low baseline magnesium status.

Lifestyle Factors That Multiply Everything Else

Dr. Froese is clear that no peptide or supplement replaces the lifestyle foundations of brain health. Exercise is consistently the single most powerful modifiable factor for dementia prevention. Regular aerobic exercise increases BDNF production, improves vascular health, enhances insulin sensitivity (insulin resistance is a risk factor for Alzheimer's), and promotes the clearance of toxic brain proteins. The evidence for exercise is so strong that if it came in a pill, it would be the best-selling pharmaceutical in history.

Sleep gets extensive attention because of its role in brain waste clearance. The glymphatic system, which clears metabolic waste products from the brain, is most active during deep sleep. Chronic sleep deprivation or poor sleep quality leads to accumulation of beta-amyloid and phosphorylated tau, the hallmark proteins of Alzheimer's disease. Seven to nine hours of quality sleep per night, with adequate deep sleep stages, is not optional for brain health. It is foundational.

Social engagement, cognitive stimulation, stress management, and blood sugar control round out the lifestyle recommendations. Each of these factors has independent evidence for dementia risk reduction, and they work synergistically. A person who exercises regularly, sleeps well, manages stress, stays socially connected, and maintains healthy blood sugar has dramatically lower dementia risk than someone who does none of these things, regardless of genetic predisposition.

Building a Practical Prevention Protocol

The practical value of this video is in the framework Dr. Froese provides for building a layered prevention strategy. The foundation is lifestyle: exercise, sleep, nutrition, stress management, and social engagement. The second layer is targeted supplementation: omega-3s, lion's mane, phosphatidylserine, and magnesium threonate. The third layer, for people who want to be more aggressive with prevention, is peptide therapy: Semax for BDNF support, Selank for stress and immune modulation, and Epithalon for telomerase activation and melatonin cycling.

This layered approach makes sense because each layer addresses different mechanisms. Lifestyle factors provide the broad foundation of metabolic and vascular health. Supplements provide specific molecular support for neuronal function. Peptides provide targeted signaling that amplifies neuroprotective and regenerative processes. Together, they create a multi-system defense that is more robust than any single intervention could be.

Dr. Froese emphasizes that starting early is the single most important variable. Brain changes associated with Alzheimer's disease begin 20 to 30 years before symptoms appear. A person who starts a full brain protection protocol at 35 has decades of accumulated benefit by the time age-related cognitive decline would typically begin. Waiting until memory problems are already noticeable means decades of damage have already occurred, and while intervention at any stage is better than none, the returns diminish significantly once the disease process is well established.

The video also raises an important point about testing and monitoring. Baseline cognitive testing, inflammatory markers (CRP, IL-6), metabolic markers (fasting insulin, HbA1c), and hormonal panels provide a starting point for measuring the effectiveness of any prevention strategy. Repeating these tests annually allows for early detection of trends that might warrant additional intervention before they progress to clinical significance. This proactive monitoring approach is at the heart of functional medicine's philosophy, and it applies powerfully to brain health where early intervention has the highest impact.

Why Most People Wait Too Long to Start Prevention

The most sobering message in this video is about timing. Alzheimer's pathology begins 20 to 30 years before the first clinical symptoms. By the time someone notices memory problems significant enough to mention to a doctor, the disease process has been running for decades. At that point, interventions can slow further decline but cannot reverse the damage already done. The beta-amyloid plaques and tau tangles that define Alzheimer's have been accumulating since the patient's 40s or 50s, silently destroying neural connections before any symptoms were apparent.

Dr. Froese argues that this timeline should fundamentally change how we think about brain health. Instead of reactive medicine, where we wait for problems and then try to fix them, brain health demands proactive medicine that starts decades before problems would be expected. A 35-year-old who begins a full brain protection protocol, even one as simple as regular exercise, omega-3 supplementation, and sleep optimization, has 20 to 30 years of accumulated neuroprotective benefit by the time age-related cognitive decline would typically become noticeable.

The financial argument supports early intervention as well. Dementia care in the United States costs more than 350 billion dollars annually, with the average lifetime cost per patient exceeding 350,000 dollars. Even expensive prevention strategies, including peptide therapy, are trivial compared to the personal and financial cost of developing dementia. Spending 200 dollars per month on a prevention protocol is not an indulgence. Measured against the catastrophic cost of the disease it aims to prevent, it is one of the most rational health investments a person can make.